Transcatheter tricuspid repair reduces deaths and hospitalizations
The TRIC-I-HF randomized trial in Germany enrolled 360 symptomatic patients with severe tricuspid regurgitation, randomized 2:1 to transcatheter repair or medical therapy. Operators used commercially available devices, primarily TEER with Pascal (65.6%) and TriClip (33.0%). At one year the combined outcome including quality of life favored intervention (win ratio 2.42, 95% CI 1.76–3.33) and the investigators reported a number needed to treat of four to prevent one death or heart-failure hospitalization; major adverse events within 30 days occurred in 5.9% of procedures. Three-year combined outcomes also favored repair (HR 0.40, 95% CI 0.29–0.55).
Transcatheter repair cut death or heart failure hospitalization.
Context
A recent randomized trial tested tricuspid valve repair versus medicine in older patients with severe tricuspid regurgitation. The trial showed benefits in deaths, hospitalizations, and quality of life, and it was done at high-volume…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked